Nasdaq:SRZN
Surrozen, Inc./DE
A clinical-stage biotech firm developing next-generation medical devices to transform patient care diagnostics and treatments.
Key Metrics
Investment Thesis
Bull Case
Investors may be attracted by the company's unique position in a niche medical device market with high potential for regulatory approval and commercial success. The substantial cash reserves of $34.6M provide a runway to continue critical R&D initiatives without immediate dilution, though this is shrinking. Successful product launches could significantly improve margins and reverse the current negative earnings trajectory.
Bear Case
The deteriorating financial health is alarming, with net losses increasing from -$36.0M in 2022 to -$63.6M in 2024, signaling unsustainable burn rates. The company carries a significant retained earnings deficit of -$285.3M and total liabilities exceeding assets, creating a precarious balance sheet. Without immediate profitability or major external funding, the risk of insolvency or further aggressive equity dilution remains high.
About Surrozen, Inc./DE
Surrozen Inc. (SRZN) is a specialized biotechnology company focused on developing innovative medical devices and technologies to address unmet needs in patient care. The company primarily serves the healthcare sector through its proprietary product lines aimed at improving diagnostic accuracy and treatment outcomes. Key revenue streams are derived from the commercialization of these medical solutions, with significant investments directed toward research and development to sustain long-term growth.
Analysis
Management Discussion
The company reported a net loss of $63.6M in 2024, a widening trend compared to previous years, reflecting substantial cash burn and heavy investment in research and development totaling $21.1M. Despite generating positive gross profit of $10.7M, operating expenses surged to $36.2M, driven largely by general administrative costs and R&D efforts, resulting in an operating profit of -$25.5M. Cash flow from operations turned negative at -$17.6M, necessitating significant financing inflows of $16.0M from share issuances to maintain liquidity.
Industry Overview
The medical device industry is characterized by rapid technological innovation and stringent regulatory requirements that demand substantial R&D investment before product commercialization. Companies in this sector often experience long development cycles with high upfront costs but significant rewards upon successful market entry. Market dynamics are shaped by evolving healthcare policies, reimbursement rates, and the increasing demand for personalized medicine solutions.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $12.5M | $0 | $10.7M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $12.5M | $0 | $10.7M |
| Operating Expenses | $56.8M | $45.8M | $36.2M |
| Operating Income | $-44.3M | $-45.8M | $-25.5M |
| R&D | $37.0M | $27.2M | $21.1M |
| G&A | $19.8M | $15.8M | $15.1M |
| Stock-Based Comp | $4.5M | $4.4M | $4.1M |
| D&A | $2.0M | $1.9M | $1.4M |
| Other OpEx | $0 | $2.8M | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Income | $781.0K | $2.3M | $1.7M |
| Pre-Tax Income | $-44.3M | $-45.8M | $-25.5M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-44.3M | $-45.8M | $-25.5M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-36.0M | $-43.0M | $-63.6M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-36.0M | $-43.0M | $-63.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $81.3M | $41.1M | $38.9M |
| Cash & Equivalents | $24.7M | $36.0M | $34.6M |
| Marketable Securities | $51.1M | $0 | — |
| Accounts Receivable | $2.0M | $2.2M | $2.0M |
| Prepaid Expenses | $3.5M | $2.9M | $1.8M |
| Other Current Assets | $0 | $0 | $502.0K |
| Long-Term Assets | $8.1M | $4.9M | $9.5M |
| PP&E (Net) | $3.6M | $2.0M | $562.0K |
| Operating Leases | $3.3M | $1.9M | $7.8M |
| LT Securities | $0 | — | — |
| Other LT Assets | $1.2M | $1.1M | $1.2M |
| Total Assets | $89.4M | $46.1M | $48.5M |
| Current Liabilities | $9.7M | $7.1M | $7.3M |
| Accounts Payable | $658.0K | $525.0K | $306.0K |
| Current Leases | $2.2M | $2.5M | $1.8M |
| Other Current Liab | $0 | $0 | $0 |
| Long-Term Liabilities | $3.7M | $997.0K | $62.5M |
| LT Operating Leases | $3.4M | $882.0K | $6.6M |
| Other LT Liab | $326.0K | $115.0K | $55.9M |
| Total Liabilities | $13.4M | $8.1M | $69.8M |
| Shareholders' Equity | $76.0M | $37.9M | $-21.4M |
| Paid-In Capital | $254.9M | $259.6M | $263.9M |
| Retained Earnings | $-178.7M | $-221.7M | $-285.3M |
| AOCI | $-241.0K | $0 | — |
| Total L&E | $89.4M | $46.1M | $48.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-36.0M | $-43.0M | $-63.6M |
| Non-Cash Adjustments | $-4.5M | $8.6M | $48.1M |
| Working Capital Changes | $-3.6M | $-5.9M | $-2.2M |
| Cash from Operations | $-44.1M | $-40.4M | $-17.6M |
| Capital Expenditures | $728.0K | $398.0K | $26.0K |
| Cash from Investing | $38.3M | $51.7M | $-26.0K |
| Share Buybacks | $2.6M | $0 | — |
| Cash from Financing | $-2.6M | $276.0K | $16.2M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-8.4M | $11.6M | $-1.5M |
| Beginning Cash | $33.5M | $25.1M | $36.7M |
| Ending Cash | $25.1M | $36.7M | $35.3M |
Frequently Asked Questions
How does Surrozen, Inc./DE make money?
Medical device sales and licensing, Research and development services, Strategic partnerships for technology commercialization
What are the main risks for SRZN?
Significant operating losses and a substantial retained earnings deficit indicating financial distress, Heavy reliance on successful clinical trials or regulatory approvals for future revenue generation, Potential dilution from common share issuances to fund operations, Intense competition in the medical device sector with high barriers to entry
What is SRZN's competitive advantage?
Proprietary intellectual property protecting core medical technologies, Specialized expertise in advanced diagnostic solutions, Strong pipeline of innovative products targeting high-need therapeutic areas
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.